ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AMS Advanced Medical Solutions Group Plc

215.00
1.00 (0.47%)
Last Updated: 11:40:48
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions Group Plc LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.47% 215.00 213.50 215.00 216.00 212.50 216.00 66,190 11:40:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Plastics,resins,elastomers 126.21M 15.89M 0.0731 29.34 466.17M

Advanced Medical Solutions Grp PLC Annual General Meeting

12/06/2024 7:00am

RNS Regulatory News


RNS Number : 0407S
Advanced Medical Solutions Grp PLC
12 June 2024
 

12 June 2024

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will hold its Annual General Meeting at 11.00 am today at the offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.

 

Chris Meredith, AMS's Chief Executive Officer, will give a short presentation at the Annual General Meeting.  No new material information will be provided.

 

The results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.

 

 

- End -

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

ICR Consilium

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone

AMS@icrhealthcare.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

HSBC Bank plc (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made six acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, and Syntacoll, a German specialist in collagen-based absorbable surgical implants.

 

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see  www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFLFFDREILLIS

1 Year Advanced Medical Solutions Chart

1 Year Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart